Revolution Medicines, Inc. · NASDAQ:RVMD
Revolution Medicines — ESMO Asia 2025
9 slides from Revolution Medicines's conference presentation, December 2025
Slide 1: Safety and Efficacy of Elironrasib, a RAS(ON) G12C-Selective Inhibitor, in Previously Treated Patients with KRAS G12C NSCLC
Safety and Efficacy of Elironrasib, a RAS(ON) G12C-Selective Inhibitor, in Previously Treated Patients with KRAS G12C NSCLC Daniel Tan Shao Weng1, Elvire Pons-Tostivint2, Alessio Amatu3, Bruna Pellini4, Frédéric Bigot5, Loïc Verlingue6, Pasi A. Jänne7, Estelamari Rodriguez8, Omar Saavedra9, Andrea Z
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Daniel Tan Shao Weng No disclosures of interest Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Slide 3: Elironrasib - A Differentiated RAS(ON) G12C-Selective Tri-Complex Inhibitor
Elironrasib - A Differentiated RAS(ON) G12C-Selective Tri-Complex Inhibitor • Elironrasib (RMC-6291) is a RAS(ON) G12C-selective tri-complex inhibitor that inhibits RAS G12C in its GTP-bound active form • Elironrasib has been granted FDA Breakthrough Therapy Designation for the treatment of patients
Slide 4: RMC-6291-001 Phase I Study Design
RMC-6291-001 Phase I Study Design Dose Escalation Baseline characteristics of patients with KRAS G12C NSCLC who Elironrasib administered orally QD or BID have not received prior therapy with a KRAS(OFF) G12C inhibitor 21-day treatment cycle 200 mg BID Baseline Characteristics N = 36 400 mg BID Age,
Slide 5: Treatment-Related Adverse Events in KRAS(OFF) G12C Inhibitor-Naïve NSCLC Patients
Treatment-Related Adverse Events in KRAS(OFF) G12C Inhibitor-Naïve NSCLC Patients 200 mg BID Total (N = 36) Any Grade Grade 1 Grade 2 Grade 3 Grade 4/5 Any TRAE by Preferred Term (occurring in ≥10%), n (%) 28 (78) 13 (36) 8 (22) 7 (19) 0 Diarrhea 12 (33) 8 (22) 2 (6) 2 (6) 0 ECG QTc prolonged 9 (25)
Slide 6: Objective Response Rate and Duration of Response in KRAS(OFF) G12C Inhibitor-Naïve NSCLC Patients
Objective Response Rate and Duration of Response in KRAS(OFF) G12C Inhibitor-Naïve NSCLC Patients 100 Tumor Response (per RECIST 1.1) 75 KRAS G12C Naïve to G12Ci Best overall response, n (%) inhibitor-Naïve = On treatment (N = 36) Best % Change in SOD from Baseline 50 Complete response 2 (6) in Targ
Slide 7: Progression-Free Survival and Overall Survival in KRAS(OFF) G12C Inhibitor-Naïve NSCLC Patients
Progression-Free Survival and Overall Survival in KRAS(OFF) G12C Inhibitor-Naïve NSCLC Patients Median PFS, months (95% CI): 10.3 (6.2-NE) Median OS, months (95% CI): NE (11.4-NE) 100 100 12-mo OS rate: 65% (46%-78%) 6-mo PFS rate: 76% (58%-87%) 90 90 Median OS, months (95% CI): NE (11.4-NE) 80 12-m
Slide 8: Conclusions
Conclusions • Elironrasib 200 mg BID as monotherapy has demonstrated promising initial clinical activity in patients with KRAS G12C NSCLC who have been previously treated with chemotherapy and immunotherapy but did not receive a KRAS(OFF) G12C inhibitor • In this patient population, elironrasib 200
Slide 9: European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org esmo.org